Eyenovia, Inc. Announces Closing of Offering of Common Stock
August 21 2020 - 4:05PM
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose array
print (MAP™) therapeutics, today announced the closing of its
previously announced underwritten public offering of 3,333,334
shares of its common stock at a price to the public of $3.60 per
share.
The net proceeds to Eyenovia from the public offering, after
deducting underwriting discounts and commissions and offering
expenses payable by Eyenovia, were approximately $10.9 million.
Eyenovia intends to use the net proceeds from the public offering,
together with existing funds, to fund the continued clinical
development of its product candidates, initial commercialization
activities for MicroStat, and for working capital and general
corporate purposes.
William Blair & Company, L.L.C. acted as the sole
book-running manager for the offering. National Securities
Corporation acted as the co-manager for the offering.
The offering was made pursuant to a shelf registration statement
on Form S-3 (File No. 333-229365) that was declared effective by
the Securities and Exchange Commission (the “SEC”) on February 12,
2019. A final prospectus supplement related to the offering has
been filed with the SEC and is available on the SEC’s website,
located at www.sec.gov. Copies of the final prospectus supplement
and the accompanying prospectus relating to the offering may also
be obtained from William Blair & Company, L.L.C., Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago, IL
60606, or by calling (800) 621-0687, or emailing
prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any offer or sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose array
print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused
on the late-stage development of microdosed medications for
presbyopia, myopia progression and mydriasis. For more Information,
please visit www.eyenovia.com.
Forward-Looking Statements
Except for historical information, all of the statements,
expectations, and assumptions contained in this press release are
forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any
other statements relating to our future activities or other future
events or conditions. These statements are based on current
expectations, estimates and projections about our business based,
in part, on assumptions made by management. These statements are
not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and are likely to,
differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors discussed from
time to time in documents which we file with the SEC. In addition,
such statements could be affected by risks and uncertainties
related to, among other things, the Company’s expectations
regarding its anticipated use of the net proceeds from the public
offering, its need to raise additional capital even after this
financing, and other risks and uncertainties described in
Eyenovia’s filings with the SEC. Any forward-looking statements
speak only as of the date on which they are made, and except as may
be required under applicable securities laws, Eyenovia does not
undertake any obligation to update any forward-looking
statements.
Company Contact:Eyenovia, Inc.John
GandolfoChief Financial Officerjgandolfo@eyenoviabio.com
Investor Contact:The Ruth GroupAlexander
LoboPhone: 646-536-7037alobo@theruthgroup.com
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Sep 2023 to Sep 2024